Dexcom (DXCM) Gross Profit (2010 - 2026)

Dexcom (DXCM) has 17 years of Gross Profit data on file, last reported at $750.3 million in Q1 2026.

• Quarterly Gross Profit rose 27.39% year-over-year to $750.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 billion (up 20.2% YoY) and the FY2025 annual result came in at $2.8 billion, up 14.92% from the prior year.
• Gross Profit declined to $750.3 million in Q1 2026 per DXCM's latest filing, from $792.7 million in the prior quarter.
• Across five years, Gross Profit topped out at $792.7 million in Q4 2025 and bottomed at $398.1 million in Q1 2022.
• The 5-year median for Gross Profit is $593.8 million (2024), against an average of $597.8 million.
• The widest annual swing landed in 2024, when Gross Profit retreated 4.73%; it then advanced 27.39% in 2026.
• Tracing DXCM's Gross Profit over 5 years: stood at $541.3 million in 2022, then advanced by 21.3% to $656.6 million in 2023, then retreated by 0.12% to $655.8 million in 2024, then increased by 20.88% to $792.7 million in 2025, then decreased by 5.35% to $750.3 million in 2026.
• Per Business Quant, the three latest DXCM Gross Profit figures stand at $750.3 million (Q1 2026), $792.7 million (Q4 2025), and $731.4 million (Q3 2025).

Peer Comparison